Dexmedetomidine inhibits lipid peroxidation in anticipated ischaemia-reperfusion injury .
Dexmedetomidine reduces the ischemia-reperfusion injury markers during upper extremity surgery with tourniquet
J Hand Surg Am. 2008 Jul-Aug;33(6):941-7.40 patients (ASA Grade 1 to 2) scheduled to undergo hand and forearm surgery with tourniquet and brachial plexus anesthesia via axillary approach for upper-limb block were randomized to receive a continuous infusion of dexmedetomidine or saline as placebo until the end of surgery. Following evaluations over a 2 week period, results exhibited that the dexmedetomidine treatment led to a significant decrease the plasma hypoxanthine production in ischemic period and plasma malondialdehyde production in the reperfusion periods. The dexmedetomidine group had significantly lower blood creatine phosphokinase and uric acid levels after reperfusion compared to the control group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
